News
MSLE
6.95
-7.21%
-0.54
Analysts Offer Insights on Healthcare Companies: Satellos Bioscience (MSLE) and Protara Therapeutics (TARA)
TipRanks · 1d ago
Weekly Report: what happened at MSLE last week (1102-1106)?
Weekly Report · 1d ago
Satellos Changes BASECAMP Endpoint After FDA Feedback; Data Expected In Q1 2027
NASDAQ · 4d ago
Satellos Changes Primary Endpoint in Pediatric Duchenne Trial After FDA Feedback
TipRanks · 4d ago
Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback
Benzinga · 4d ago
Satellos to Update Investors on BASECAMP DMD Study Strategy
TipRanks · 5d ago
Weekly Report: what happened at MSLE last week (1026-1030)?
Weekly Report · 11/02 09:13
Weekly Report: what happened at MSLE last week (1019-1023)?
Weekly Report · 10/26 09:13
Satellos Bioscience to Court Investors at November Healthcare Conferences
TipRanks · 10/21 11:27
Weekly Report: what happened at MSLE last week (1012-1016)?
Weekly Report · 10/19 09:13
Weekly Report: what happened at MSLE last week (1005-1009)?
Weekly Report · 10/12 09:14
Satellos management to meet with Cantor
TipRanks · 10/08 20:55
Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Benzinga · 10/08 18:01
Craig-Hallum initiates Satellos with a Buy ahead of BASECAMP data
TipRanks · 10/08 13:10
Satellos initiated with a Buy at Craig-Hallum
TipRanks · 10/08 11:36
Satellos Secures Long-Term U.S. Patent Protection for Lead Drug Forazapadin
TipRanks · 10/05 11:28
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform
Benzinga · 10/05 11:10
Weekly Report: what happened at MSLE last week (0928-1002)?
Weekly Report · 10/05 09:14
Analyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress
TipRanks · 10/01 00:35
Satellos Completes Enrollment In Phase 2 Forazapadin Trial For DMD
NASDAQ · 09/30 12:23
More
Webull provides a variety of real-time MSLE stock news. You can receive the latest news about Satellos Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About MSLE
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.